CF102: Compassionate use program started

Can-Fite said the Israeli Ministry of Health approved the use of oral CF102 for a patient with HCC under the country’s compassionate use program. The patient was previously enrolled in Can-Fite’s Israeli Phase I/II trial of CF102 in HCC and has survived for about 5 years. CF102 is also in a Phase II trial to treat advanced HCC with Child-Pugh Class B cirrhosis in patients who have failed Nexavar sorafenib. CF102 has Orphan Drug designation in the U.S. to treat HCC. ...